Flow cytometric 3-color analysis of circulating activated platelets and its clinical significance in ischemic cerebrovascular diseases
Wang, J.; Cao, L.; He, M.
Zhonghua Yi Xue Za Zhi 80(7): 499-502
2000
ISSN/ISBN: 0376-2491 PMID: 11798806 Document Number: 524464
To explore the flow cytometric 3-color analysis of circulating activated platelets (CAP) and its clinical significance in ischemic cerebrovascular diseases. The fibrinogen receptor (FIB-R) and P-selectin (CD62P) were used for molecular marker of CAP, which were analyzed by flow cytometric 3-color immunofluorescence. Expression of FIB-R and CD62P on the resting platelet membrane surface was very lower in normal individuals, the median of FIB-R and CD62P positive percent was 1.40% and 0.70% respectively. Platelet can be obviously activated by 0.1 micromol/L ADP, and 10.0 micromol/L ADP leaded to the peak expression of FIB-R and CD62P on the activated platelet membrane surface, FIB-R and CD62P positive percent of 87.8% and 81.34% respectively. That monoclonal antibody of the FIB-R combined with ADP activating platelets was inhibited by synthetic peptide (RGDS). The quantity of CAP with FIB-R expression was markedly higher (P < 0.01) and the amount of CAP with CD62P expression was not significantly higher (P > 0.05) in blood of 112 patients with thrombotic tendency and 120 patients with ischemic cerebrovascular diseases than in healthy individuals. The expression of CAP with FIB-R of in front and behind treatment of acute cerebral infarction continuously decreased (P < 0.05), and the quantity of CAP with FIB-R expression was related negatively to Europe stroke score (ESS) of patients with acute cerebral infarction. The FIB-R may be regarded as sensitive and specific molecular marker in detection of CAP. The level of platelet activation in vivo can be reflected accurately by flow cytometric 3-color analysis of CAP, which has an important clinical significance for the study of pathogenesis, estimation of prognosis and supervision of curative effect in ischemic cerebrovascular diseases.